Glympse Bio raises more than $46M in Series B round for biosensor technology
The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.
Glympse Bio raises $22 million in Series A round for disease monitoring tech
ARCH Ventures and LS Polaris Innovation Fund led the round, which the company will use to develop the tech in diseases like NASH, its lead indication.
As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.